Structure via PubChem · Public domain (PubChem)
brivaracetam
Sign in to saveAlso known as 2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide, compound 83α, UCB 34714, UCB-34714, UCB34714
Brivaracetam, sold under the brand name Briviact among others, is a chemical analog of levetiracetam, a racetam derivative with anticonvulsant (antiepileptic) properties. It has been approved since 2016. It is marketed by the pharmaceutical company UCB. It is used to treat partial-onset seizures with or without secondary generalisation, in combination with other antiepileptic drugs.
Key facts
- Drug.imageL
- Brivaracetam.svg
- Drug.image_classL
- skin-invert-image
- Drug.widthL
- 130
- Drug.imageR
- Brivaracetam ball-and-stick model from xtal 2018.png
- Drug.image_classR
- bg-transparent
- Drug.widthR
- 110
- Drug.tradename
- Briviact, Nubriveo, Brivajoy
- Drug.MedlinePlus
- a616027
- Drug.DailyMedID
- Brivaracetam
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- By mouth, intravenous
- Drug.ATC_prefix
- N03
- Drug.ATC_suffix
- AX23
- Drug.legal_AU
- S4
- Drug.legal_BR
- C1
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Schedule V
- Drug.legal_EU
- Rx-only
via Wikipedia infobox
Chemical data
- Formula
- C11H20N2O2
- Molecular weight
- 212.29 g/mol
- IUPAC name
- (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide
- SMILES
- CCC[C@@H]1CC(=O)N(C1)[C@@H](CC)C(=O)N
- InChIKey
- MSYKRHVOOPPJKU-BDAKNGLRSA-N
- XLogP
- 1
- Polar surface area
- 63.4 Ų
- H-bond donors
- 1
- H-bond acceptors
- 2
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2016
- Admin. routes
- oral, parenteral
- Indications
- epilepsy, Seizure, Unverricht-Lundborg disease, Spinal cord injury
via ChEMBL · EBI
Research
639 papers- Brivaracetam.2012
- Brivaracetam.Australian prescriber · 2017
- Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy.Advances in therapy · 2024
- PMID 288462162017
- Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review.Epilepsy & behavior : E&B · 2021
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 212.152478
Show 6 more facts
- chemical formula
- C₁₁H₂₀N₂O₂
- isomeric SMILES
- CCC[C@@H]1CC(=O)N(C1)[C@@H](CC)C(=O)N
- canonical SMILES
- CCCC1CC(=O)N(C1)C(CC)C(=O)N
- subject has role
- anticonvulsant agent
- medical condition treated
- epilepsy
- Commons category
- Brivaracetam
Sources (6)
via Wikidata · CC0
~6 min read
Encyclopedic overview
12 sectionsContents
- Medical uses
- Adverse effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Pharmacogenetics
- Chemical and physical properties
- History
- Society and culture
- References
- Further reading
Brivaracetam, sold under the brand name Briviact among others, is a chemical analog of levetiracetam, a racetam derivative with anticonvulsant (antiepileptic) properties. It has been approved since 2016. It is marketed by the pharmaceutical company UCB. It is used to treat partial-onset seizures with or without secondary generalisation, in combination with other antiepileptic drugs.
==Medical uses== Brivaracetam is used to treat partial-onset seizures with or without secondary generalisation, in combination with other antiepileptic drugs. Efficacy and tolerability is comparable in general and Intellectual Disability populations. No data are available for its effectiveness and safety in people younger than 16 years of age.
Excerpted from Wikipedia’s “brivaracetam” article, available under the CC BY-SA 4.0 licence.